Well, NRMX is on MY short list if your quote from the statisticians is accurate. Given the nearly meaningless data-point changes necessary for statistical significance in Alzheimer's studies (CIBIC, CDR, and/or ADAS scores) and the huge numbers of subjects necessary to generate a powerful enough statistical paradigm, having your statistician tell you that your not going to make it is BAD news for clinical utility for the drug.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.